Fulcrum Therapeutics® to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 11, 2022 at 8:00 a.m. ET

Rhea-AI Summary

Fulcrum Therapeutics, Inc. (Nasdaq: FULC) will release its second quarter 2022 financial results on August 11, 2022, before the U.S. markets open. The company, focused on treating genetically defined rare diseases, will host a conference call at 8:00 a.m. ET for discussions regarding the results and recent developments. Key programs include losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease. A webcast will also be available for those unable to join live.

Positive

• Upcoming financial results expected on August 11, 2022.
• Focused on high unmet medical needs with innovative therapies.

Negative

• None.

CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its second quarter 2022 financial results will be released on Thursday, August 11, 2022 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Dial-in Number
U.S. Dial-in Number: 833-634-2546
International Dial-in Number: 412-902-4190
All participants should ask to be connected to the Fulcrum Therapeutics conference call.

Replay U.S. Dial-in Number: 877-344-7529
Replay Canada Dial-In Number: 855-669-9658
Replay International Dial-in Number: 412-317-0088
Replay Access Code: 7096297

An audio webcast will be accessible through the Investor Relations section of the company’s website https://ir.fulcrumtx.com/events-and-presentations. Following the live webcast, an archived replay will also be available.

About Fulcrum Therapeutics 
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD) and other hemoglobinopathies, including beta-thalassemia. The company’s proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, please visit www.fulcrumtx.com.

Contacts:

Investors
Stephanie Ascher
Stern Investor Relations, Inc.
stephanie.ascher@sternir.com
212-362-1200

Media
Dee Smith
Executive Director, Corporate Communications
Fulcrum Therapeutics, Inc.
dsmith@fulcrumtx.com
202-746-1324

FAQ

When will Fulcrum Therapeutics release its second quarter 2022 financial results?

Fulcrum Therapeutics will release its second quarter 2022 financial results on August 11, 2022, before U.S. markets open.

What programs is Fulcrum Therapeutics developing?

Fulcrum Therapeutics is developing losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease.

What time is the conference call for Fulcrum Therapeutics' financial results?

The conference call will take place at 8:00 a.m. ET on August 11, 2022.

How can I access the webcast for Fulcrum Therapeutics' financial results?

The webcast can be accessed through the Investor Relations section of the Fulcrum Therapeutics website.